Abstract
Personalized treatment using stem, modified or genetically engineered, cells is becoming a reality in the field of medicine, in which allogenic or autologous cells can be used for treatment and possibly for early diagnosis of diseases. Hematopoietic, stromal and organ specific stem cells are under evaluation for cell-based therapies for cardiac, neurological, autoimmune and other disorders. Cytotoxic or genetically altered T-cells are under clinical trial for the treatment of hematopoietic or other malignant diseases. Before using stem cells in clinical trials, translational research in experimental animal models are essential, with a critical emphasis on developing noninvasive methods for tracking the temporal and spatial homing of these cells to target tissues. Moreover, it is necessary to determine the transplanted cells, engraftment efficiency and functional capability. Various in vivo imaging modalities are in use to track the movement and incorporation of administered cells. Tagging cells with reporter genes, fluorescent dyes or different contrast agents transforms them into cellular probes or imaging agents. Recent reports have shown that magnetically labeled cells can be used as cellular magnetic resonance imaging (MRI) probes, demonstrating the cell trafficking to target tissues. In this review, we will discuss the methods to transform cells into probes for in vivo imaging, along with their advantages and disadvantages as well as the future clinical applicability of cellular imaging method and corresponding imaging modality.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 19-38 |
| Number of pages | 20 |
| Journal | Current Medical Imaging Reviews |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jun 2 2009 |
Fingerprint
Keywords
- Cell tracking
- Cellular magnetic resonance (CMRI)
- Magnetic cell labeling
- SPION
- Stem cells
ASJC Scopus subject areas
- Internal Medicine
- Radiology Nuclear Medicine and imaging
Cite this
In vivo cellular imaging for translational medical research. / Arbab, Ali Syed; Janic, Branislava; Haller, Jodi; Pawelczyk, Edyta; Liu, Wei; Frank, Joseph A.
In: Current Medical Imaging Reviews, Vol. 5, No. 1, 02.06.2009, p. 19-38.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - In vivo cellular imaging for translational medical research
AU - Arbab, Ali Syed
AU - Janic, Branislava
AU - Haller, Jodi
AU - Pawelczyk, Edyta
AU - Liu, Wei
AU - Frank, Joseph A.
PY - 2009/6/2
Y1 - 2009/6/2
N2 - Personalized treatment using stem, modified or genetically engineered, cells is becoming a reality in the field of medicine, in which allogenic or autologous cells can be used for treatment and possibly for early diagnosis of diseases. Hematopoietic, stromal and organ specific stem cells are under evaluation for cell-based therapies for cardiac, neurological, autoimmune and other disorders. Cytotoxic or genetically altered T-cells are under clinical trial for the treatment of hematopoietic or other malignant diseases. Before using stem cells in clinical trials, translational research in experimental animal models are essential, with a critical emphasis on developing noninvasive methods for tracking the temporal and spatial homing of these cells to target tissues. Moreover, it is necessary to determine the transplanted cells, engraftment efficiency and functional capability. Various in vivo imaging modalities are in use to track the movement and incorporation of administered cells. Tagging cells with reporter genes, fluorescent dyes or different contrast agents transforms them into cellular probes or imaging agents. Recent reports have shown that magnetically labeled cells can be used as cellular magnetic resonance imaging (MRI) probes, demonstrating the cell trafficking to target tissues. In this review, we will discuss the methods to transform cells into probes for in vivo imaging, along with their advantages and disadvantages as well as the future clinical applicability of cellular imaging method and corresponding imaging modality.
AB - Personalized treatment using stem, modified or genetically engineered, cells is becoming a reality in the field of medicine, in which allogenic or autologous cells can be used for treatment and possibly for early diagnosis of diseases. Hematopoietic, stromal and organ specific stem cells are under evaluation for cell-based therapies for cardiac, neurological, autoimmune and other disorders. Cytotoxic or genetically altered T-cells are under clinical trial for the treatment of hematopoietic or other malignant diseases. Before using stem cells in clinical trials, translational research in experimental animal models are essential, with a critical emphasis on developing noninvasive methods for tracking the temporal and spatial homing of these cells to target tissues. Moreover, it is necessary to determine the transplanted cells, engraftment efficiency and functional capability. Various in vivo imaging modalities are in use to track the movement and incorporation of administered cells. Tagging cells with reporter genes, fluorescent dyes or different contrast agents transforms them into cellular probes or imaging agents. Recent reports have shown that magnetically labeled cells can be used as cellular magnetic resonance imaging (MRI) probes, demonstrating the cell trafficking to target tissues. In this review, we will discuss the methods to transform cells into probes for in vivo imaging, along with their advantages and disadvantages as well as the future clinical applicability of cellular imaging method and corresponding imaging modality.
KW - Cell tracking
KW - Cellular magnetic resonance (CMRI)
KW - Magnetic cell labeling
KW - SPION
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=66049115520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66049115520&partnerID=8YFLogxK
U2 - 10.2174/157340509787354697
DO - 10.2174/157340509787354697
M3 - Review article
AN - SCOPUS:66049115520
VL - 5
SP - 19
EP - 38
JO - Current Medical Imaging Reviews
JF - Current Medical Imaging Reviews
SN - 1573-4056
IS - 1
ER -